204 related articles for article (PubMed ID: 15206013)
1. Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.
Hollen PJ; Gralla RJ; Rittenberg CN
Support Care Cancer; 2004 Nov; 12(11):767-73. PubMed ID: 15206013
[TBL] [Abstract][Full Text] [Related]
2. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
[TBL] [Abstract][Full Text] [Related]
3. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
4. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
5. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Bezjak A; Lee CW; Ding K; Brundage M; Winton T; Graham B; Whitehead M; Johnson DH; Livingston RB; Seymour L; Shepherd FA
J Clin Oncol; 2008 Nov; 26(31):5052-9. PubMed ID: 18809617
[TBL] [Abstract][Full Text] [Related]
6. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
7. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
9. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer.
Tanvetyanon T; Soares HP; Djulbegovic B; Jacobsen PB; Bepler G
J Thorac Oncol; 2007 Dec; 2(12):1091-7. PubMed ID: 18090580
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N; Takigawa N; Hotta K; Segawa Y; Kato Y; Kozuki T; Oze I; Kishino D; Aoe K; Ueoka H; Kuyama S; Harita S; Okada T; Hosokawa S; Inoue K; Gemba K; Shibayama T; Tabata M; Takemoto M; Kanazawa S; Tanimoto M; Kiura K
Lung Cancer; 2015 Feb; 87(2):141-7. PubMed ID: 25534129
[TBL] [Abstract][Full Text] [Related]
12. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.
Van Schil PE
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):718; author reply 718-9. PubMed ID: 18329516
[No Abstract] [Full Text] [Related]
13. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
[TBL] [Abstract][Full Text] [Related]
14. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
15. The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer.
Schulte T; Schniewind B; Dohrmann P; Küchler T; Kurdow R
Chest; 2009 Feb; 135(2):322-329. PubMed ID: 18689576
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
Brundage MD; Mackillop WJ
J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
18. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
20. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]